Mechanisms of atherogenic effects of bisphenol A
双酚A致动脉粥样硬化作用的机制
基本信息
- 批准号:8828205
- 负责人:
- 金额:$ 18.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-04-01 至 2017-09-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAffectAgonistAnimal ModelAnimalsApoE knockout mouseApolipoprotein EArterial Fatty StreakAtherosclerosisBiologicalBiological MonitoringBone Marrow TransplantationCD36 geneCardiovascular DiseasesChemicalsChronicDevelopmentDietary SteroidDoseEnvironmentEtiologyExhibitsExposure toFoam CellsFutureGenesGoalsHealthHormonesHumanIndividualLigandsLinkLipidsMediatingMolecularMusNuclear ReceptorsPathway interactionsPharmacologic SubstancePharmacologyPilot ProjectsPlayPopulationProductionReceptor ActivationRiskRisk AssessmentRoleSpecificityTestingTransgenesTransgenic MiceUncertaintyVariantXenobiotic MetabolismXenobioticsatherogenesisbasebisphenol Ablood lipidcardiovascular disorder riskconsumer productenvironmental chemicalexposed human populationgene environment interactionhuman population studyin vivoleukocyte activationmacrophagenovelpolycarbonate plasticpopulation basedpregnane X receptorreceptorscavenger receptorsensorspecies difference
项目摘要
DESCRIPTION (provided by applicant): This is an R21 application intended to investigate the mechanisms of atherogenic effects of bisphenol A (BPA). BPA is a base chemical used extensively in polycarbonate plastics in many consumer products, and human exposure to BPA is ubiquitous. Higher BPA exposure has recently been associated with an increased risk of cardiovascular disease (CVD) in multiple human population-based studies. However, the mechanisms responsible for these associations remain unknown. Many environmental chemicals can activate the xenobiotic receptor pregnane X receptor (PXR) which, in turn, acts as a xenobiotic sensor to regulate xenobiotic metabolism and exhibits considerable differences in its pharmacology across species. Very recently, we revealed PXR's pro-atherogenic effects in animal models and found that chronic activation of mouse PXR increases atherosclerosis in atherosclerosis-prone apolipoprotein E deficient (ApoE-/-) mice. We also demonstrated that BPA is a potent activator of human but not mouse PXR, consequently, the choice of animal model is paramount in predicting the human risk assessment of BPA. Therefore, we generated novel PXR- humanized ApoE-/- mice (huPXR.ApoE-/-, i.e., ApoE knockout mice with the human PXR transgene in place of mouse PXR) that can respond to human PXR ligands. Our central hypothesis is that chronic activation of PXR by exposure to BPA promotes foam cell formation and increases atherosclerotic lesion formation in PXR- humanized mice, thereby increasing the risk of CVD in exposed individuals. Two specific aims are proposed to test this hypothesis: 1) Does chronic exposure to BPA at doses relevant to human exposure increase atherosclerosis in PXR-humanized ApoE-/- mice? 2) What molecular pathway does BPA act through to influence atherogenesis? The proposed studies are the first to investigate the effects of BPA exposure on atherosclerosis in a suitable animal model, and to explore the precise molecular mechanisms by which BPA induces CVD at the molecular level.
描述(由申请人提供):这是一项R21申请,旨在研究双酚A(BPA)致动脉粥样硬化作用的机制。BPA是一种基础化学品,广泛用于许多消费品中的聚碳酸酯塑料,人类暴露于BPA是普遍存在的。最近,在多项基于人群的研究中,较高的BPA暴露与心血管疾病(CVD)风险增加有关。然而,负责这些联系的机制仍然不明。许多环境化学物质可以激活异生素受体--异生素X受体(PXR),PXR作为异生素感受器调节异生素代谢,并在不同物种间表现出相当大的药理学差异。最近,我们在动物模型中揭示了PXR的促动脉粥样硬化作用,并发现小鼠PXR的慢性激活增加了易患动脉粥样硬化的载脂蛋白E缺陷(ApoE-/-)小鼠的动脉粥样硬化。我们还证明了BPA是人类而不是小鼠PXR的有效激活剂,因此,动物模型的选择在预测BPA的人类风险评估中至关重要。因此,我们产生了新的PXR-人源化ApoE-/-小鼠(huPXR.ApoE-/-,即,用人PXR转基因代替小鼠PXR的ApoE敲除小鼠),其可以对人PXR配体产生应答。我们的中心假设是,暴露于BPA的PXR慢性激活促进泡沫细胞形成,并增加PXR人源化小鼠动脉粥样硬化病变的形成,从而增加暴露个体的CVD风险。提出了两个具体的目标来检验这一假设:1)在PXR人源化ApoE-/-小鼠中,以与人类暴露相关的剂量长期暴露于BPA是否会增加动脉粥样硬化?2)BPA通过什么样的分子途径影响动脉粥样硬化的发生?这些研究首次在合适的动物模型中研究了BPA暴露对动脉粥样硬化的影响,并在分子水平上探索了BPA诱导CVD的精确分子机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Changcheng Zhou其他文献
Changcheng Zhou的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Changcheng Zhou', 18)}}的其他基金
Role of PXR in EDC-induced cardiovascular disease
PXR 在 EDC 诱发的心血管疾病中的作用
- 批准号:
10640665 - 财政年份:2023
- 资助金额:
$ 18.8万 - 项目类别:
Core D - Energy Balance and Body Composition Core
核心 D - 能量平衡和身体成分核心
- 批准号:
10225373 - 财政年份:2018
- 资助金额:
$ 18.8万 - 项目类别:
Core D - Energy Balance and Body Composition Core
核心 D - 能量平衡和身体成分核心
- 批准号:
10458566 - 财政年份:2018
- 资助金额:
$ 18.8万 - 项目类别:
Core D - Energy Balance and Body Composition Core
核心 D - 能量平衡和身体成分核心
- 批准号:
9982358 - 财政年份:2018
- 资助金额:
$ 18.8万 - 项目类别:
Role of IKKβ in obesity and atherosclerosis
IKKβ 在肥胖和动脉粥样硬化中的作用
- 批准号:
10008480 - 财政年份:2016
- 资助金额:
$ 18.8万 - 项目类别:
A novel mechanism for ART-associated dyslipidemia and atherosclerosis
ART 相关血脂异常和动脉粥样硬化的新机制
- 批准号:
9109680 - 财政年份:2015
- 资助金额:
$ 18.8万 - 项目类别:
A novel mechanism for ART-associated dyslipidemia and atherosclerosis
ART 相关血脂异常和动脉粥样硬化的新机制
- 批准号:
9273599 - 财政年份:2015
- 资助金额:
$ 18.8万 - 项目类别:
Mechanisms of atherogenic effects of bisphenol A
双酚A致动脉粥样硬化作用的机制
- 批准号:
8638093 - 财政年份:2014
- 资助金额:
$ 18.8万 - 项目类别:
Endocrine disruptor mediated activation of PXR causes dyslipidemia
内分泌干扰物介导的 PXR 激活导致血脂异常
- 批准号:
8743207 - 财政年份:2013
- 资助金额:
$ 18.8万 - 项目类别:
Endocrine disruptor mediated activation of PXR causes dyslipidemia
内分泌干扰物介导的 PXR 激活导致血脂异常
- 批准号:
9308696 - 财政年份:2013
- 资助金额:
$ 18.8万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 18.8万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 18.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 18.8万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 18.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 18.8万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 18.8万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 18.8万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 18.8万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 18.8万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 18.8万 - 项目类别:
Studentship














{{item.name}}会员




